Objectives: To test CIDP patients for IgM positivity towards NF140.
Patients:
| Number | Code |
|---|---|
| 1 | 18-532 |
| 2 | 18-533 |
| 3 | 18-534 |
| 4 | 18-535 |
| 5 | 18-356 |
| 6 | 18-537 |
| 7 | 18-538 |
| 8 | 18-539 |
| 9 | 18-540 |
| 10 | 18-541 |
| 11 | 18-542 |
| 12 | 18-543 |
| 13 | 18-544 |
| 14 | 18-545 |
| 15 | 18-546 |
| 16 | 18-547 |
| 17 | 18-548 |
| 18 | 18-549 |
| 19 | 18-550 |
| 20 | 18-551 |
| 21 | 18-552 |
| 22 | 18-553 |
| 23 | 18-554 |
| 24 | CTRL - |
NF140 ICC:
- HEKs 293 Cells Transfection: 2017.08.30
- Blocking solution: 5% goat serum in PBS.
- Patient’s sera diluted 1/10 for IgM with 5% goat serum in PBS.
- Primary antibody: AF3235 diluted 1/1000.
- Secondary antibodies: GAH 594 IgM (1/1000) + GAC 488 IgG (1/1000).
- Vectashield mounting medium
Results: We found a questionable positive result in patients 18-532, 18-533, 18-541, 18-546, 18-551, 18-553. We suspect a crossreactivity between the comercial AF3235 and the secondary antibody GAH 594 IgM; so we are going to perform another experiment with ICC confronting the sera of the patient 18-532 and the secondary Ab without AF3235, and confronting AF3235 and GAH 594 IgM without any sera.
